1. Home
  2. TGLS vs NUVB Comparison

TGLS vs NUVB Comparison

Compare TGLS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$39.45

Market Cap

1.8B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.25

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGLS
NUVB
Founded
1984
2018
Country
United States
United States
Employees
N/A
298
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
TGLS
NUVB
Price
$39.45
$4.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$63.33
$11.38
AVG Volume (30 Days)
309.6K
4.3M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
1.41%
N/A
EPS Growth
N/A
N/A
EPS
0.71
N/A
Revenue
$370,984,000.00
N/A
Revenue This Year
$13.56
$203.82
Revenue Next Year
$9.04
$58.18
P/E Ratio
$54.41
N/A
Revenue Growth
17.98
N/A
52 Week Low
$37.52
$1.57
52 Week High
$90.34
$9.75

Technical Indicators

Market Signals
Indicator
TGLS
NUVB
Relative Strength Index (RSI) 42.36 38.01
Support Level N/A $4.07
Resistance Level $46.89 $5.23
Average True Range (ATR) 2.05 0.30
MACD -0.28 -0.04
Stochastic Oscillator 20.29 15.24

Price Performance

Historical Comparison
TGLS
NUVB

About TGLS Tecnoglass Inc.

Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: